| Question 1: What is the intent of ICRU Report No. 96? |
| Reference: | Sgouros G, Bolch WE, Chiti A, et al. ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. Journal of the ICRU. 2021;21(1):1-212 |
| Choice A: | to review the physics and dosimetry of RPT |
| Choice B: | to provide guidance on best practices for dosimetry-driven implementation of RPT |
| Choice C: | to standardize practices for clinical trial studies |
| Choice D: | all of the above |
| Question 2: Why are different levels of dosimetry and reporting listed? |
| Reference: | Sgouros G, Bolch WE, Chiti A, et al. ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. Journal of the ICRU. 2021;21(1):1-212 |
| Choice A: | to make sure that practitioners only use one of the three listed levels |
| Choice B: | to make it clear that they are all equivalent and differ only in terms of techniques used |
| Choice C: | to accommodate different levels of practice and resource availability while encouraging transition to the best practice level |
| Choice D: | to highlight dosimetry practices that should be avoided |
| Question 3: For a given kind of radiopharmaceutical therapy, the term "dosimetric treatment regions" (DTR), as specified in ICRU report 96, intends to encompass |
| Reference: | Sgouros G, Bolch WE, Chiti A, et al. ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. Journal of the ICRU. 2021;21(1):1-212 |
| Choice A: | tumors or other regions of disease for which dosimetry is made; they are a subset of the clinical treatment region |
| Choice B: | normal organs that limit the activity to be administered to a patient |
| Choice C: | the entire burden of disease for a patient, also including any microscopic disease |
| Choice D: | all organs and tissues that are irradiated during therapy |
| Question 4: Which of these statements is incorrect? |
| Reference: | Hobbs RF, Sgouros G. Calculation of the biological effective dose (BED) for piece-wise defined dose-rate fits. Med Phys. 2009;36:904–907.
Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 2010; 51(2):311–28.
RF Hobbs, RW Howell, H Song, S Baechler, G Sgouros. “Redefining relative biological effectiveness in the context of the EQDX formalism: Implications for alpha-particle emitter therapy”. Radiat Res 2014, 181(1):90-98.
Sgouros G, Bolch WE, Chiti A, et al. ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. Journal of the ICRU. 2021;21(1):1-212. |
| Choice A: | The equieffective dose (EQDX) is directly proportional to the absorbed dose for a given organ and modality |
| Choice B: | Equieffective dose (EQDX) depends on dose rate as well as absorbed dose |
| Choice C: | The BED is the same as EQD0 |
| Choice D: | Alpha-particle absorbed dose multiplied by the sRBEX should be expressed in units of Gy, not Sv |
| Question 5: The time-integrated activity for 90Y microsphere dosimetry can be estimated based on physical decay because |
| Reference: | Dezarn WA, Cessna JT, DeWerd LA, et al. American Association of Physicists in Medicine. Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies. Med Phys. 2011 Aug;38(8):4824-45.
Sgouros G, Bolch WE, Chiti A, et al. ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. Journal of the ICRU. 2021;21(1):1-212. |
| Choice A: | 90Y has a short half-life |
| Choice B: | microspheres are trapped and typically do not redistribute |
| Choice C: | 90Y has a long half-life |
| Choice D: | 90Y is a pure beta emitter |
| Question 6: In radiopharmaceutical therapy, a Level 2 dosimetry report as specified in ICRU report 96 should include |
| Reference: | Sgouros G, Bolch WE, Chiti A, et al. ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. Journal of the ICRU. 2021;21(1):1-212 |
| Choice A: | The absorbed dose to all organs and tumors |
| Choice B: | The absorbed dose to all source regions (SR) |
| Choice C: | The absorbed dose to all localization regions (LR) |
| Choice D: | The absorbed dose to the dosimetric treatment regions (DTR) and regions at risk (RAR) |
